Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.41 Billion
CAGR (2026-2031)	18.17%
Fastest Growing Segment	Multi-antigen
Largest Market	North America
Market Size (2031)	USD 3.84 Billion

Market Overview

The Global Malaria Vaccine Market will grow from USD 1.41 Billion in 2025 to USD 3.84 Billion by 2031 at a 18.17% CAGR. The Global Malaria Vaccine Market encompasses the development and distribution of biological preparations designed to provide acquired immunity against Plasmodium parasites. The primary drivers fueling this market include the urgent mandate to lower disease burden in high-transmission regions and the robust procurement mechanisms established by international health organizations. These structural supports create a stable demand foundation that is separate from evolving technological trends, ensuring that the market growth relies on long-term public health strategies rather than temporary shifts in research preferences.

However, the market faces a substantial challenge regarding the gap between manufacturing capacity and the immediate scale of global demand, as supply chain bottlenecks often hinder the timely delivery of these interventions to remote locations. According to Gavi, the Vaccine Alliance, in 2024, more than 10.5 million malaria vaccine doses were procured and delivered to 17 endemic countries. This statistic underscores the significant logistical pressures and the critical necessity for expanded production capabilities within the current market landscape.

Key Market Drivers

Integration of Malaria Vaccines into National Routine Immunization Schedules acts as the primary catalyst for market expansion, shifting the landscape from limited pilot programs to widespread national adoption. This transition significantly increases the addressable patient population, necessitating robust supply chains and government commitment to ensuring consistent delivery. According to Gavi, the Vaccine Alliance, April 2025, in the 'Rolling out vaccines to beat malaria together' report, a total of 25 countries had been approved for funding to support malaria vaccine introductions, reflecting a rapid escalation in demand beyond the initial pilot nations. To sustain this broad rollout, procurement agencies are actively negotiating favorable commercial terms to maximize coverage within budget constraints. According to UNICEF, November 2025, in the 'Gavi and UNICEF announce equitable pricing deal' press release, a new supply agreement secured savings of up to US$ 90 million, directly enabling the procurement of millions of additional doses for at-risk populations.

Increased Funding and Procurement Commitments from major international bodies provide the essential financial stability required for manufacturers to scale operations. Unlike private markets driven by fluctuating consumer purchasing power, this sector relies on sustained donor capital to bridge the gap between production costs and affordability in low-income nations. These financial guarantees allow pharmaceutical developers to invest in long-term capacity expansion without bearing the full risk of market volatility. According to Gavi, in 2025, the organization outlined plans to invest more than US$ 1.1 billion in malaria vaccination programmes during its 2026–2030 strategic period. This long-term assurance is critical for aligning manufacturing output with the global health agenda of eradicating the disease.

Download Free Sample Report

Key Market Challenges

The disconnect between limited manufacturing capacity and the immediate scale of global demand acts as a severe constriction on the growth of the Global Malaria Vaccine Market. While international mandates generate substantial order volumes, the complex biological production processes required for these interventions prevent manufacturers from rapidly scaling output to match this surge in interest. This disparity creates a market environment where potential revenue is deferred, and the widespread adoption necessary for substantial market valuation is physically restricted by product unavailability.

Consequently, supply chain bottlenecks and rigid production ceilings force implementing organizations to ration distributions rather than fulfill the total market potential. This inability to service the total addressable market effectively caps the industry's growth rate. According to UNICEF, in 2024, the secured supply of the RTS,S vaccine was restricted to approximately 18 million doses for the entire 2023–2025 period, a volume that significantly trailed the immediate requirements of eligible nations. Such constraints ensure that the market remains smaller in practice than projected by demand models, as growth is dictated by logistical feasibility rather than buyer intent.

Key Market Trends

Advancement of Next-Generation mRNA Vaccine Platforms represents a critical technological pivot designed to transcend the efficacy limitations of first-generation protein-based formulations. Developers are leveraging this scalable architecture to target multiple parasite stages, aiming to accelerate design iterations and improve durability against the complex Plasmodium pathogen. However, the transition to these novel mechanisms faces rigorous regulatory scrutiny inherent to experimental biological platforms, creating intermittent delays in clinical progression. According to Contagion Live, March 2025, in the 'FDA Pauses BioNTech's Malaria Vaccine Trial Amid Broader Vaccine Challenges' article, the US FDA placed a clinical hold on the Phase I/II trial of the mRNA vaccine candidate BNT165e, which had enrolled nearly 180 participants, highlighting the stringent safety protocols governing this platform's advancement.

Localization of Manufacturing Capabilities in Endemic Regions is simultaneously reshaping the global supply landscape by moving production closer to high-burden populations. This structural trend aims to reduce dependency on centralized intercontinental supply chains, thereby mitigating the logistical risks associated with importing finished doses. International health agencies are actively capitalizing regional autonomy by financing infrastructure that allows African nations to manage their own health security. According to the World Health Organization, August 2025, in the 'Health leaders, partners pledge to catalyse Africa's production of medicines and vaccines' report, Unitaid committed nearly US$ 50 million to flagship programmes designed to boost Africa's capacity to locally produce essential medical diagnostics and therapeutics.

Segmental Insights

Market analysis identifies Multi-antigen as the fastest-growing segment within the Global Malaria Vaccine Market. This accelerated growth stems from the critical necessity to enhance immune protection beyond the moderate efficacy offered by current single-stage options. By combining components that target multiple phases of the Plasmodium life cycle, including the liver and blood stages, Multi-antigen vaccines aim to prevent parasite escape and induce a more durable immune response. Consequently, this segment is witnessing substantial investment as developers strive to meet the rigorous efficacy goals established by the World Health Organization for long-term malaria control and eradication.

Regional Insights

North America dominates the Global Malaria Vaccine Market, primarily due to its extensive infrastructure for research and development. This leadership position is reinforced by the concentration of prominent biotechnology firms and pharmaceutical manufacturers that actively drive vaccine discovery within the region. Additionally, substantial financial backing and strategic initiatives from key institutions, such as the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH), play a critical role in accelerating clinical advancements. The region’s proactive regulatory framework and established healthcare sector further support this growth, ensuring North America remains the central hub for funding and developing malaria interventions.

Recent Developments

• In June 2025, Bharat Biotech entered into a strategic collaboration with GlaxoSmithKline to significantly reduce the cost of the Mosquirix (RTS,S) malaria vaccine. The agreement outlined a plan to lower the price per dose to less than $5 by 2028, thereby enhancing accessibility for children in low-income, malaria-endemic countries. Under the terms of the partnership, Bharat Biotech agreed to assume responsibility for manufacturing the vaccine's antigen, while GlaxoSmithKline committed to continuing the supply of the adjuvant. This initiative involved a technology transfer process designed to expand global production capacity and ensure a sustainable long-term supply chain for the immunization.
• In March 2025, BioNTech disclosed that the U.S. Food and Drug Administration had placed a clinical hold on the Phase 1/2a clinical trial of its mRNA-based malaria vaccine candidate, BNT165e. The regulatory action paused the study, which was designed to evaluate the safety, tolerability, and efficacy of the multi-antigen vaccine in healthy adults in the United States. The company confirmed its compliance with the order and stated that it was actively working with the regulatory body to address specific requests and determine the future path for the program. This development represented a critical juncture in the company's application of its proprietary mRNA technology platform to address infectious diseases beyond COVID-19.
• In August 2024, Sanaria Inc. announced breakthrough research findings published in The Lancet Infectious Diseases regarding its PfSPZ Vaccine. The clinical trials, conducted in Mali, demonstrated that the vaccine provided high-level, durable protection against malaria infection in women who were vaccinated prior to conception. The data revealed that the vaccine maintained its efficacy over a two-year period without the need for a booster dose, a unique characteristic among current malaria vaccine candidates. This development highlighted the potential of the company's whole-parasite vaccine platform to effectively safeguard vulnerable populations, specifically pregnant women, who have historically been difficult to protect with existing preventative measures.
• In May 2024, the Serum Institute of India achieved a significant commercial milestone by dispatching its initial shipment of the R21/Matrix-M malaria vaccine to the Central African Republic. This event marked the commencement of the vaccine's large-scale rollout in Africa, following its prequalification by the World Health Organization. The vaccine, developed in partnership with the University of Oxford and utilizing Novavax's adjuvant technology, was designed to be a cost-effective solution for malaria-endemic regions. The company allocated a substantial number of doses for this initial delivery, aiming to support the immunization of children and demonstrating its capacity to scale manufacturing to meet global public health demands.

Key Market Players

• GlaxoSmithKline, Plc.
• Novartis AG
• Takeda Pharmaceutical Company
• Sanaria Inc.
• Merck & Co.
• Johnson & Johnson
• Pfizer Inc.
• Serum Institute of India Private Limited
• Bharat Biotech International Limited
• Moderna Inc

By Vaccine Type	By Route of Administration	By Region
Pre-Erythrocytic Erythrocytic Multi-antigen Others	Intramuscular Subcutaneous Intradermal Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Malaria Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Malaria Vaccine Market, By Vaccine Type:

• Pre-Erythrocytic
• Erythrocytic
• Multi-antigen
• Others

• Malaria Vaccine Market, By Route of Administration:

• Intramuscular
• Subcutaneous
• Intradermal
• Others

• Malaria Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE